PFIZER INC.

At ESMO's annual meeting, Pfizer's ponsegromab showed promise in treating cancer cachexia, helping patients regain weight and improve symptoms. Johnson & Johnson's TAR-200, a chemotherapy-releasing device, demonstrated efficacy in bladder cancer, with 42% of patients showing no cancer evidence. BioNTech and Instil Bio presented early data on drugs targeting PD1 and VEGF, similar to Summit Therapeutics' successful trial. Long-term studies revealed Keytruda's superior survival rates over Yervoy in melanoma patients. Scorpion Therapeutics' STX-478 showed potential as a PI3Ka inhibitor with manageable side effects.

Novo Nordisk's liraglutide Phase III trial in children under 12 showed a 13-point increase in Likelihood of Approval (LoA) to 50% for obesity. Pfizer's maplirpacept saw its Phase Transition Success Rate (PTSR) drop after a Phase I trial termination. Vaxcyte's VAX-31 pneumonia vaccine and Atsena Therapeutics' ATSN-101 for Leber Congenital Amaurosis (LCA) both reported positive Phase I/II trial results, increasing their PTSR. Les Laboratoires Servier's oncology Phase I trial termination led to a decline in PTSR for S-64315 and S-65487 in non-Hodgkin lymphoma (NHL), acute myeloid leukaemia (AML), and multiple myeloma (MM).

Novo Nordisk's liraglutide Phase III trial in children under 12 showed a -7.4% BMI difference favoring liraglutide. Pfizer's maplirpacept saw PTSR drop after Phase I termination. Vaxcyte's VAX-31 vaccine reported positive Phase I/II data. Atsena Therapeutics's ATSN-101 in rare disease ophthalmology met all endpoints. Les Laboratoires's oncology Phase I trial was terminated.

The Renal Cell Carcinoma Clinical Trial Pipeline Market is projected to grow significantly from 2024 to 2031, driven by technological innovations, rising demand, and regulatory changes. The market is segmented by type and application, with key players including Amgen, AstraZeneca, and Pfizer. Clinical trials focus on novel therapies, drug combinations, and targeted treatments, aiming to improve outcomes for renal cell carcinoma patients.

Pfizer announced positive results for ponsegromab in a Phase 2 trial for treating cancer cachexia, with plans for late-stage trials next year. The drug showed improvements in body weight, muscle mass, quality of life, and physical function.

Pfizer’s ponsegromab, a GDF-15-targeting antibody, achieved clinically meaningful weight gain in a Phase II trial for cancer cachexia patients, with plans to start a pivotal programme in 2025.

Pfizer's Phase 2 study of ponsegromab met its primary endpoint, showing a 5.6% mean increase in body weight at the highest dose compared to placebo in cancer cachexia patients. Ponsegromab was generally safe and well-tolerated, with improvements in appetite, cachexia symptoms, physical activity, and muscle mass. Registration-enabling studies are planned to start in 2025.

The statins market, valued at $22B, is projected to reach $15B by 2021, driven by cardiovascular disease prevalence, cholesterol management awareness, and statin formulation advancements. Challenges include generic competition, alternative therapies, and side effects. Opportunities lie in combination therapies and emerging markets.

Pembrolizumab (Keytruda) showed sustained survival benefits over ipilimumab (Yervoy) in unresectable stage III or IV melanoma patients, with 10-year follow-up data from the KEYNOTE-006 study presented at the 2024 ESMO Congress. Pembrolizumab had a median overall survival (OS) of 32.7 months vs 15.9 months for ipilimumab, with 8- and 10-year OS rates of 36.9% and 34.0% vs 24.8% and 23.6%, respectively. The study also highlighted the safety profile and long-term efficacy of pembrolizumab, supporting its standard of care status in advanced melanoma.